Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

This trial is testing a triple combination of drugs — venetoclax, azacitidine, and chidamide — for newly diagnosed acute monocytic leukemia (a specific subtype of blood cancer called AML-M5) in patients who are not fit enough for intensive chemotherapy. The three drugs work together to stop cancer cell growth and promote cell death. **You may be eligible if...** - You have been newly diagnosed with acute monocytic leukemia (AML-M5) - You are 60 years of age or older, OR between 18–59 with serious health problems that make intensive chemotherapy too risky (such as heart disease, poor lung function, or kidney issues) - You have not received prior treatment for this leukemia - You are expected to survive at least 12 weeks - You meet laboratory requirements (blood counts, liver function, etc.) **You may NOT be eligible if...** - You have already received chemotherapy, radiation, or a stem cell transplant in the past 4 weeks - You are pregnant or breastfeeding - You have health conditions that make you ineligible based on your doctor's assessment Talk to your doctor to see if this trial is right for you.